Literature DB >> 20460892

Adaptive immunity in autoimmune hepatitis.

Maria Serena Longhi1, Yun Ma, Giorgina Mieli-Vergani, Diego Vergani.   

Abstract

The histological lesion of interface hepatitis, with its dense portal cell infiltrate consisting of lymphocytes, monocytes/macrophages and plasma cells, was the first to suggest an autoaggressive cellular immune attack in the pathogenesis of autoimmune hepatitis (AIH). Immunohistochemical studies, focused on the phenotype of inflammatory cells infiltrating the liver parenchyma, have shown a predominance of alphabeta-T cells. Amongst these cells, the majority have been CD4 helper/inducers, while a sizeable minority have consisted of CD8 cytotoxic/suppressors. Lymphocytes on non-T cell lineage included natural killer cells, monocytes/macrophages and B lymphocytes. For autoimmunity to arise, the self-antigenic peptide, embraced by an human leukocyte antigen (HLA) class II molecule, must be presented to an uncommitted T helper (T(H)0) lymphocyte by professional antigen-presenting cells. Once activated and according to the presence in the milieu of interleukin 12 (IL-12) or IL-4, T(H)0 lymphocytes can differentiate into T(H)1 cells, which are pivotal to macrophage activation; enhance HLA class I expression, rendering liver cells vulnerable to CD8 T-cell attack; and induce HLA class II expression on hepatocytes; or they can differentiate into T(H)2 cells, which produce IL-4, IL-10 and IL-13, cytokines favouring autoantibody production by B lymphocytes. Autoantigen recognition is tightly controlled by regulatory mechanisms, such as those exerted by CD4+CD25(high) regulatory T cells. Numerical and functional regulatory T cell impairment characterises AIH and permits the perpetuation of effector immune responses with ensuing persistent liver destruction. Advances in the study of autoreactive T cells stem mostly from AIH type 2, where the main autoantigen, cytochrome P450IID6 (CYP2D6), is known to enable characterisation of antigen-specific immune responses. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460892     DOI: 10.1159/000282066

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  4 in total

Review 1.  Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation.

Authors:  B Brooks-Worrell; J P Palmer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 2.  HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition.

Authors:  Michael Campoli; Soldano Ferrone
Journal:  Semin Immunopathol       Date:  2011-04-28       Impact factor: 9.623

3.  Activated natural killer T cells producing interferon-gamma elicit promoting activity to murine dendritic cell-based autoimmune hepatic inflammation.

Authors:  M Nakano; C Saeki; H Takahashi; S Homma; H Tajiri; M Zeniya
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

4.  Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases.

Authors:  Dilyara Akberova; Andrei P Kiassov; Diana Abdulganieva
Journal:  J Immunol Res       Date:  2017-02-19       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.